In:
Personalized Medicine, Future Medicine Ltd, Vol. 19, No. 3 ( 2022-05), p. 207-217
Abstract:
Plain language summary Ticagrelor is one of the main antiplatelet drugs used for prevention of coronary blood clots after interventional procedures in patients with acute coronary syndromes. It has previously been shown that gene variants of CYP2C19 and CYP4F2 may affect antiplatelet therapy. This paper reports a novel instrument and the results of genetic tests obtained using this instrument. Our instrument can detect variants of the genes associated with ticagrelor antiplatelet therapy in only 40 min. These findings might facilitate individualized treatment with ticagrelor of patients with ST-elevation myocardial infarction.
Type of Medium:
Online Resource
ISSN:
1741-0541
,
1744-828X
DOI:
10.2217/pme-2021-0152
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022
SSG:
15,3
